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Abstract: Antipsychotics are the mainstay in schizophrenia management, and long-acting
injectable (LAI) antipsychotics contribute to the successful maintenance of treatment by
improving non-adherence and preventing relapses. Paliperidone palmitate 3-monthly (PP3M)
formulation is the only available LAI antipsychotic that offers an extended 3-month window of
stable plasma drug concentration, enabling only four injections per year. This paper sum-
marizes clinically relevant endpoints from available evidence for PP3M to bridge translational
research gaps and provide measurable outcomes that can be interpreted in clinical practice.
Low number-needed-to-treat (NNT) for relapse prevention (NNT [95% CI] 6-month estimate:
4.8 [3.2; 10.0]; 12-month estimate: 3.4 [2.2; 7.0]), and high number-needed-to-harm (NNH
[95% CI] akathisia, 27.1 [12.3; −667.1]; tremor, 80.0 [22.5; 67.3]; dyskinesia, −132.6 [44.5;
−23.2]; parkinsonism, 160.0 [28.9; −49.8]) quantify the relative beneﬁts and low propensity for
adverse events with PP3M. Symptom remission and reductions in positive and negative
symptoms indicate treatment stability. Additionally, meaningful functional remission, reduced
dosing frequency, and freedom from daily negotiations favorably impact patient preference and
attenuate burdensome aspects of caregiving, representing important healthcare determinants
that enhance prospects of treatment continuity in schizophrenia. This information can poten-
tially improve clinicians’ judgment of treatment choices, clinical response, and patient selec-
tion in routine care. Taken together, PP3M is a valuable antipsychotic treatment option,
meriting consideration for a broader role in the long-term management of schizophrenia; its
utility should not be limited to patients with poor adherence or when oral antipsychotics have
failed.
Keywords: number-needed-to-harm, number-needed-to-treat, paliperidone palmitate
3-monthly, remission
Introduction
Schizophrenia is a complex psychiatric disorder with a variable trajectory of
symptomatic status that may include stabilization, remission, relapse, deterioration,
or total incapacitation.1,2 Clinical studies evaluating antipsychotics for schizophre-
nia are replete with data; however, discerning the data in a clinically useful way is
often difﬁcult.3 Assessment of antipsychotics using valid indicators of treatment
effects would assist clinicians and psychiatrists with robust, reliable, and compara-
tive data for making treatment decisions.4 Such indicators would include percep-
tible symptomatic and functional improvements or treatment differences, risk–
beneﬁt balance, and factors inﬂuencing patient’s and caregiver’s well-being that
are not merely based on statistical signiﬁcance and would reinforce the utility of
antipsychotics in routine clinical practice.5
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Non-adherence or gaps in antipsychotic use increase the
odds of relapse, hospitalization, and suicidal attempts, and
restrict translation of putative treatment beneﬁts of antipsy-
chotics in real-world clinical practice.6–10 Partial adherence
(<80%) has been directly correlated with risk of hospitaliza-
tion, and a gap of 1–10 days in oral antipsychotic (OAP)
treatment coverage has been shown to increase the odds of
hospitalization (odds ratio [OR]=1.98).11,12 Long-acting
injectable (LAI) antipsychotics facilitate adherence by redu-
cing dosing frequency, offering reliable medication delivery,
stable pharmacokinetics, and allowing regular monitoring of
dose administration.13
Paliperidone, the major active metabolite of
the second-generation antipsychotic (SGA) risperidone, is
a centrally-active antagonist of the D2 and 5HT2A
receptors.14 Paliperidone extended-release (ER), the oral
formulation (approved in 2006), has demonstrated efﬁcacy
with improvements in symptom control, patient function-
ing, and relapse prevention in several randomized-
controlled trials (RCTs) conducted to date.15–18 Its ﬁrst
LAI formulation, paliperidone palmitate once-monthly
(PP1M), allows once-monthly administration, thereby
improving prospects for medication adherence, and is
approved (in 2009) for the treatment of schizophrenia.19
PP1M as deltoid or gluteal injections is available in multi-
ple dosing strengths (25, 50, 75, 100, or 150 mg eq.
[corresponding doses in mg paliperidone palmitate:
39 mg, 78 mg, 117 mg, 156 mg, and 234 mg]) for ease
of dose titration.14,20 PP1M has shown robust efﬁcacy in
attenuating psychotic symptoms, improving functional sta-
tus, and relapse prevention, along with meaningful reduc-
tions in hospitalizations, meriting consideration as a viable
choice for schizophrenia management at different stages of
illness.21–27 PP1M has also shown efﬁcacy in delaying
time-to-relapse for psychotic, depressive, and manic symp-
toms and improvements in the level of functioning in
schizoaffective disorder, and is approved for this indica-
tion in some countries.28,29
Pharmacological prospects and clinical experience
from the PP1M formulation supported the use of model-
based pharmacometric analysis to develop a modiﬁed,
extended-release LAI formulation of PP, paliperidone pal-
mitate 3-monthly (PP3M), for the maintenance treatment
of schizophrenia with only four injections per year.30 The
PP3M formulation (approved by the US FDA in 2015 and
by the European Medicines Agency in 2016) is indicated
for the treatment of schizophrenia; initiation requires clin-
ical stability with at least 4 months of PP1M treatment that
allows clinicians to optimize the dose and derive the
equivalent PP3M dose (3.5-fold dose multiplier of
PP1M) adequate to maintain stable paliperidone
exposure.30,31 The available doses for PP3M administered
as either deltoid or gluteal injection are 175, 263, 350, and
525 mg eq. (corresponding doses in mg: 273, 410, 546,
and 819 mg).31,32 Efﬁcacy and safety data for PP3M have
been largely accrued from two phase 3 studies (a placebo-
controlled relapse prevention study and a non-inferiority
[vs PP1M] study), wherein PP3M has shown favorable
clinical outcomes in relapse prevention, symptom remis-
sion, and functional recovery.33,34
The purpose of the current paper is to summarize and
interpret data for PP3M from the two large controlled
trials, focusing on the evaluation of clinically meaningful
endpoints and results.33,34 The paper also summarizes
empirical evidence for paliperidone ER and PP1M within
the context of ﬁndings for PP3M.
Studies, evaluations, and deﬁnitions
The majority of clinical data for PP3M were derived from
the ﬁnal analyses and multiple post hoc and subgroup
analyses of two large RCTs of PP3M.33,34 The ﬁrst RCT
comparing the efﬁcacy and safety of PP3M vs placebo was
conducted across 64 centers in eight countries.33 Patients
received PP1M during a 17-week open-label (OL) transi-
tion phase, received a single dose of PP3M in a 12-week
OL maintenance phase, and were randomized (n=305) to
PP3M or placebo in the double-blind (DB) treatment
phase.33 The second RCT demonstrating the non-
inferiority of PP3M vs PP1M was conducted across 199
centers in 26 countries.34 Patients received PP1M during
a 17-week OL stabilization phase and were randomized
(n=1,016) to PP3M or PP1M in the double-blind (DB)
treatment phase.34 A ﬁxed dosing regimen was implemen-
ted for PP3M and PP1M in both studies, and the patients
did not require any dose adjustments during the span of
these studies.33,34 In addition to the ﬁndings from these
studies, the data were analyzed in the following ways to
examine the clinical relevance of PP3M treatment.
Measures of effect sizes (to quantify a clinical response)
such as number-needed-to-treat (NNT) and number-needed-
to-harm (NNH) were used to indicate the number of patients
who will likely need to be treated with the study treatment to
beneﬁt, or result in harm, in a single patient more than with
placebo, respectively.35–37 NNTwas calculated for response
of positive and negative symptoms, as well as symptomatic
and functional remission; NNH was calculated for overall
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extrapyramidal symptoms (EPS), headache, weight gain,
nasopharyngitis, and use of anticholinergic medications dur-
ing the DB phase of the study as the reciprocal of the
absolute difference in event rates.37 The proportion of
patients using anticholinergic medications was used as an
indirect measure of clinically relevant EPS-related events.37
To support the NNT calculation for time-to-relapse, the
survival probability (based on Kaplan-Meier method) at
ﬁxed time points (6 and 12 months) was also calculated.
The conﬁdence interval (CI) for NNT for relapse prevention
was calculated based on the Altman and Andersen38 method.
CIs for NNH were derived based on the Wilson score
method using SAS 9.2 (Cary, NC, USA).39 Other measures,
such as standardized mean differences (SMD) along with
their CIs, were also presented.40
Symptomatic remission was interpreted using the
Andreasen et al41 remission criteria, and improvements in
functional status were assessed using the validated Personal
and Social Performance (PSP) scale.42,43 The Andreasen
et al41 remission criteria for schizophrenia exclusively
include the symptomatic component and do not necessitate
complete absence of symptoms, considering the chronic and
relapsing nature of the illness.44 The criteria deﬁne sympto-
matic remission as a rating of no more than mild in four core
positive and four core negative symptoms on the Positive
and Negative Syndrome Scale (PANSS)45 (P1, G9, P3, P2,
G5, N1, N4, N6) that is sustained for ≥6 months.41
The consequences of PP1M and PP3M treatment on
caregiver burden were analyzed using pooled data from the
two phase 3 studies of PP3M.46 The Involvement Evaluation
Questionnaire (IEQ) was used to measure overall caregiver
burden and important domains of care.47 The Medication
Preference Questionnaire (MPQ) was used to assess the
attitude and preference of patients towards PP3M.48
Efﬁcacy and outcomes for PP3M
treatment in schizophrenia
Relapse prevention
PP3M signiﬁcantly delayed the time to ﬁrst relapse
vs placebo (hazard ratio=3.81 [95% CI=2.08; 6.99];
P<0.001).33 As assessed by relapse rates, PP3M was sig-
niﬁcantly more efﬁcacious than placebo (incidence of
relapse: PP3M, 8.8% [14/160]; placebo, 29.0% [42/
145]).33 In addition, PP3M was non-inferior to PP1M in
terms of relapse rates and relapse-free percentage (incidence
of relapse: PP3M, 8.1% [37/458]; PP1M, 9.2% [45/490];
percentage relapse-free: PP3M, 91.2%; PP1M, 90%; differ-
ence in relapse-free rate: 1.2% [95% CI=−2.7%; 5.1%]).34
In the placebo-controlled studies, the median time-to-
relapse was not estimable for all three paliperidone formula-
tions (Table 1). In an additional assessment, the estimated
time point when 15% patients experience a relapse event was
longer in paliperidone ER and PP1M vs the respective pla-
cebo groups, and non-estimable in the PP3M group. In an
indirect comparison of three similarly-designed relapse pre-
vention studies conducted with different formulations of
paliperidone, post-withdrawal median time-to-impending-
relapse (Table 1) was increased with longer half-life
formulations.23 The median time until half of the respective
sample had relapsed was 58 days for patients discontinuing
paliperidone ER, compared to 172 days after discontinuing
Table 1 Relapse rates in placebo controlled studies with three formulations of paliperidone (ITT ﬁnal analysis set)
Oral paliperidone ER
study17
Paliperidone palmitate once-
monthly study21
Paliperidone palmitate
3-monthly study33
Pali ER,
n=104
Placebo,
n=101
PP1M,
n=205
Placebo,
n=203
PP3M,
n=160
Placebo,
n=145
Relapsed, n (%) 23 (22.1) 52 (51.5) 36 (17.6) 97 (47.8) 14 (8.8) 42 (29.0)
Median time-to-relapse (95%
CI), days
NE 58.0 (42.0;114.0)23 NE 172.0
(134.0; 222.0)23
NE 395.0 (274.0;
NE)23
Time-to-relapse in 15% of
patients, days
32 (15, 68) 22 (14,23) 115 (74, 206) 49 (41, 57) NE 86 (68, 121)
Hazard ratio, placebo/paliperi-
done formulation (95% CI)
2.83 (1.73; 4.63)
P<0.001*
3.60 (2.45; 5.28)
P<0.0001*
3.81 (2.08; 6.99)
P<0.001*
Note: *Log-rank test.
Abbreviations: CI, conﬁdence interval; ITT, intent-to-treat; NE, non-estimable; Pali ER, Paliperidone extended-release; PP1M, paliperidone palmitate once-monthly; PP3M,
paliperidone palmitate 3-monthly.
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PP1M, and 395 days after discontinuing PP3M. Having been
on PP3M prior to discontinuation and placebo-substitution
showed signiﬁcant advantages (P<0.0001, pair-wise compar-
ison) compared to PP1M and oral formulations.23 These
differences underscore clinical beneﬁts, as the relapse-risk
was signiﬁcantly lower (P<0.001) in patients discontinuing
PP LAIs as compared with paliperidone ER, and lower
(P<0.001) in patients discontinuing PP3M vs those disconti-
nuing PP1M.23
PP1M had low NNT (2 to 3), suggesting favorable efﬁ-
cacy for relapse prevention, consistent with the reported
relapse prevention efﬁcacy.21,37 The NNT (95% CI) with
PP3M for relapse prevention was calculated at two time
points (6 and 12 months). At both time points, the NNTs to
prevent relapse relative to placebo were low (NNT [95%CI]:
6-month, ﬁnal analysis=4.8 [3.2; 10.0]; 12-month, ﬁnal ana-
lysis=3.4 [2.2; 7.0]), thus supporting the relapse prevention
efﬁcacy from the primary phase 3 study.33,39 The NNTs for
PP3M were comparable to PP1M (Table 2).37 Overall, the
NNT data imply low risk of relapse with PP3M maintenance
treatment in schizophrenia.39
Positive symptoms
In the phase 3 non-inferiority study, improvements in
positive and negative symptoms were observed with
PP1M treatment during the OL phase that were sustained
through the DB phase for both PP1M and PP3M groups
(Table 3).34 In the OL phase of the placebo-controlled
study, PP1M and PP3M treatment improved positive
symptoms. At DB endpoint, PP3M treatment signiﬁ-
cantly improved (P<0.001) positive symptoms vs -
placebo.33 Treatment with PP1M has also shown
improvements in positive symptoms in patients with
recent-onset or chronic schizophrenia, acute schizophre-
nia, as well as hospitalized patients with exacerbated
symptoms.49–53 NNT (95% CI) with PP3M treatment
for a minimally important change (percent reduction
based on ≥20% improvement) in PANSS positive sub-
scale was also low (6.9 [4.1, 23.8]; PP1M: 6.6 [4.4,
13.7]) and the SMD (95% CI) was 0.71 (0.474; 0.940);
PP1M: 0.67 (0.468; 0.869) suggesting favorable
improvements (Table 2). Overall, these results suggest
meaningful improvements in typical psychotic behavior
of schizophrenia and potential for clinically meaningful
outcomes with PP3M treatment.
Negative symptoms
In a post-hoc analysis of the phase 3 non-inferiority
study of PP3M vs PP1M, the negative subscale and
negative symptoms factor scores showed continuous
Table 2 Number needed to treat and standardized mean difference for selected clinical outcomes with different formulations of
paliperidone palmitate
PP3M PP1M
NNT (95% CI), efﬁcacy outcomes
Relapse prevention
6-month estimate 4.8 (3.2; 10.0) 3 (2.3; 4.2)
12-month estimate 3.4 (2.2; 7.0) 2 (1.5; 2.7)
PANSS Totala 14.9 (6.2; −34.4) 10.2 (5.7; 51.5)
Positive subscale 6.9 (4.1; 23.8) 6.6 (4.4; 13.7)
Negative subscale 18.6 (6.7; −24.2) 9.7 (5.5; 41.6)
General psychopathology 10.6 (5.2; −135.9) 8.5 (5.1; 25.9)
SMD (95% CI), efﬁcacy outcomes
PANSS Total 0.62 (0.389; 0.852) 0.59 (0.390; 0.788)
Positive subscale 0.71 (0.474; 0.940) 0.67 (0.468; 0.869)
Negative subscale 0.27 (0.040; 0.495) 0.28 (0.087; 0.479)
General psychopathology 0.55 (0.314; 0.775) 0.57 (0.367; 0.765)
CGI-S 0.41 (0.177; 0.634) 0.51 (0.315; 0.711)
PSP 0.46 (0.232; 0.692) 0.45 (0.250; 0.651)
Note: a≥20% improvement in PANSS and subscales.
Abbreviations: CGI-S, Clinical Global Impressions Severity subscale; CI, conﬁdence interval; NNT, number needed to treat; PANSS, Positive and Negative Syndrome Scale;
PP1M, paliperidone palmitate once-monthly; PP3M, paliperidone palmitate 3-monthly; PSP, Personal and Social Performance Scale; SMD, standardized mean difference.
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improvements throughout the OL and DB phases of the
study.54 The mean (SD) change from baseline in PANSS
negative subscale score for PP1M vs PP3M were similar
over time (DB baseline to DB endpoint: −1.4 [3.67],
R2=0.06 vs −1.4 [3.63], R2=0.05).54 In addition, the
NNT (95% CI) values for achieving ≥20% improve-
ments in PANSS negative symptoms subscale were
low for PP3M (18.6 [6.7; −24.2]) and PP1M (9.7 [5.5;
41.6]), and the SMD (95% CI) was 0.27 (0.040; 0.495)
for PP3M comparable with PP1M (0.28 [0.087; 0.479])
(Table 2). Thus, PP3M treatment has clinical beneﬁts in
the improvement of negative symptoms that are relevant
for the ultimate goal of functional recovery.55
Symptomatic remission
Post hoc analysis of data from the non-inferiority study
demonstrated that the proportion of patients achieving the
Andreasen et al criteria of 6-month remission based on the
PANSS items was similar between PP1M and PP3M
(~50% in both treatments) (Table 4).34,56 A majority of
these patients maintained their remission status throughout
the 48-week DB phase in both treatment arms.56 In
a retrospective analysis of an observational study, PP1M
treatment was associated with clinically meaningful symp-
tomatic remission (using the Structured Clinical Interview
for Symptoms of Remission [SCI-SR]) in concordance
with the rates for PP3M.57 A signiﬁcantly higher
Table 3 Improvements in positive and negative symptoms from double-blind baseline to double-blind endpoint of phase 3 PP3M
studies
Non-inferiority study (mITT DB ana-
lysis set)
Placebo-controlled study (ITT DB ana-
lysis set)
PP3M,
n=483
PP1M,
n=512
PP3M,
n=160
Placebo,
n=145
Positive symptoms
PANSS positive subscale score
Mean (SD) change from DB baseline −0.6 (4.31) −0.9 (3.70) −0.1 (2.84) 2.7 (4.92)
Difference of LS means (SE)
0.2 (0.24)
P<0.001
95% CI (−0.24; 0.72)
Positive symptoms factor
Mean (SD) change from DB baseline −1.1 (4.61) −1.4 (4.16) −0.1 (2.74) 2.5 (5.25)
Difference of LS means (SE)
0.3 (0.27)
P<0.001
95% CI (−0.21; 0.84)
Negative symptoms
PANSS negative subscale score
Mean (SD) change from DB baseline −1.4 (3.63) −1.4 (3.67) −0.1 (2.96) 0.8 (3.76)
Difference of LS means (SE)
−0.0 (0.22)
P-value=0.013
95% CI (−0.43; 0.43)
Negative symptoms factor
Mean (SD) change from DB baseline −1.4 (3.57) −1.3 (3.80) −0.3 (3.21) 0.4 (4.01)
Difference of LS means (SE)
−0.0 (0.22)
P-value=0.080
95% CI (−0.48; 0.40)
Abbreviations: CI, conﬁdence interval; DB, double-blind; ITT, intent-to-treat; LS mean, least square mean; NE, non-estimable; PANSS, Positive and Negative Syndrome
Scale; PP1M, Paliperidone palmitate once-monthly; PP3M, paliperidone palmitate 3-monthly; SD, standard deviation; SE, standard error.
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proportion of patients on PP1M (new user of PP1M:
45.0%; continuous user of PP1M: 39.0%) relative to
OAPs (23.0%) achieved remission (P<0.001). At the 12-
month follow-up, PP1M users were more likely to achieve
remission vs users of OAPs (new user of PP1M vs OAP:
OR=2.65 [1.39; 5.05]; continuous user of PP1M vs OAP:
OR=1.83 [1.03; 3.25]).57 As the majority of patients with
schizophrenia continue to be symptomatic, despite having
reductions in symptoms, the high rates of remission
obtained with PP3M treatment suggest maintenance of
clinically relevant stability, rather than only symptom
improvement.
Functional status
In the non-inferiority study, stable PSP scores in patients
treated with PP3M (27.3%) and PP1M (30.1%) suggest
a sustained effect on functioning from DB baseline to DB
endpoint (Table 4). Nearly 25% of patients on PP3M and
27% on PP1M maintained both symptomatic and func-
tional remission during the last 6 months of DB phase.56
A greater proportion of patients in both PP3M and PP1M
groups had “good PSP scores” (>70) at DB baseline
(PP3M: 28.8%; PP1M: 27.1%), as compared with OL
baseline (PP3M: 5.2%; PPIM: 5.1%), and a similar pro-
portion of patients maintained this “good PSP score” in the
last 6 months before the end of study across both treatment
arms (PP3M: 42.5%; PP1M: 43.9%). Additionally, most
patients who achieved remission at DB baseline main-
tained their remission status throughout the DB phase.
Patients’ clinical improvement was associated with greater
improvements in other PSP domains, such as social activ-
ities, personal and social relationships, self-care, disturb-
ing and aggressive behaviors, along with improvements in
insight, and social and occupational functioning
domains.56 Evaluation of functional remission based on
the duration of illness (subgroups: ≤5 years, 6–10 years,
and >10 years since diagnosis) suggested that more
patients with a recent onset (≤5 years and 6–10 years)
achieved functional remission (PSP >70) than patients
with chronic illness (>10 years) during the OL and DB
phases.58 Signiﬁcant improvements were observed in PSP
scores in the ≤5 years and 6–10 years subgroup vs the >10
years subgroup at DB baseline and DB end point
(P≤0.003), supporting early initiation of PP3M for better
functional outcomes.58
Evaluation of work functioning and productivity based
on occupational status at OL baseline in phase 3 studies of
PP3M revealed that most patients were either unemployed,
not seeking work, or retired; however, a general trend of
improvement in occupational status was observed in the
PP3M groups through the span of both studies.59 While
interpreting these ﬁndings, it should be acknowledged that
a patient’s occupational status depends on several clinical
(illness severity, symptomatic status, etc.) and social (level
of education, social support, etc.) variables, including
employment barrier and support.59 Overall, these data
suggest that PP3M treatment has wide-ranging efﬁcacy,
including improvements in functional impairment that
commonly tend to persist even after symptom reduction.
Caregiver burden
The overall caregiver burden gradually improved with
PP1M and PP3M treatment throughout the phase 3 studies
(pooled IEQ total scores change from OL baseline to DB
endpoint: −8.9 [14.73] points, n=756). Treatment with
PP1M or PP3M LAI formulation was associated with
Table 4 Remission status from double-blind randomized studies of PP3M
PP3M PP1M
Patients achieving
symptomatic
remissiona, n (%)
Patients achieving
functional
remissionb, n (%)
Patients achieving
symptomatic
remissiona, n (%)
Patients achieving
functional
remissionb, n (%)
Global
population56
243 (50.3) 132 (27.3) 260 (50.8) 154 (30.1)
European
subpopulation
125 (51.7) 61 (25.2) 128 (52.0) 75 (30.6)
East Asian
subpopulation71
85 (50.0) 49 (28.8) 87 (50.0) 50 (28.7)
Notes: aBased on Andreasen’s criteria 6-month remission based on positive and negative syndrome scale (PANSS) item scores.
bSymptomatic remission with PSP >70 during the last 6 months prior to study end.
Abbreviations: PP1M, paliperidone palmitate once-monthly; PP3M, paliperidone palmitate 3-monthly.
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improvements in urging, worrying, tension, and supervi-
sion domains, thus helping alleviate the burden on care-
givers and improving their quality-of-life (QoL).
Improvement in caregiver burden was signiﬁcantly greater
in patients without relapse (P<0.001) vs patients who
experienced relapse. In addition, switching from OAPs to
PP1M or PP3M signiﬁcantly eased the caregiver burden
and had a positive impact on the stress conditions of
caregivers (mean IEQ total score: pre-switch [at OL base-
line] 28.0 points vs post-switch [at DB endpoint] 19.3
points, P<0.001).46 Reductions in caregiver burden with
PP3M treatment were also observed across regions from
post hoc analysis of pooled data.60 It was also noted that
the perceived caregiver burden improvement was signiﬁ-
cant in patients switching from OAPs to LAI with less
leisure days impacted and less hours spent in caregiving
(P<0.001).60
Patients’ attitude and preference
In the placebo-controlled study, most patients (PP3M: 108/
150 [72.0%]; placebo: 90/135 [66.7%]) preferred to
receive the medication every 3 months based on the
MPQ analysis. The main reasons stated for this preference
were “less pain due to fewer injections” and “reduced
commuting hassles due to fewer appointments.” In the
non-inferiority study, the proportion of patients who “pre-
ferred pills” in both PP3M (23% and 21%) and PP1M
(18% and 19%) groups was similar and comparable
between OL baseline and DB endpoint. Of note however,
patients randomized to the PP3M group in this study
received an injection once a month to maintain the study
blind. Thus, the inﬂuence of once-monthly vs three-
monthly injections on patient preference remains unclear
in this study. In other studies of PP1M, patients have
recorded greater preference for LAIs over OAPs, owing
to monthly dosing ﬂexibility as opposed to daily dosing
with oral medications.48,61 From a preference survey of the
two phase 3 studies of PP3M, patients and physicians
showed greater preference for PP3M and PP1M than
OAPs (P<0.05), regardless of treatment or adherence
history.62 Patient preference was attributed to improve-
ments in positive symptoms, whereas physicians based
their choice on overall improvement (negative and positive
symptoms). Physicians also showed greater preference for
PP3M over PP1M in patients with a history of missing
20% (P=0.02) and 50% (P=0.003) of doses.62
Selection of patients for PP3M use
In a retrospective analysis of the non-inferiority study, there
were no notable differences in demographic and baseline
disease characteristics between patients on PP3M achieving
and not achieving remission.63 Overall, remitters had a robust
symptomatic proﬁle during the 17-week PP1M treatment OL
phase. Early improvements observed from week 5 and sus-
tained through week 17 were associated with better prospects
for remission. Remitters had greater improvement on the
PANSS, PSP, and CGI-S (Clinical Global Impression–
Severity)64 scores, and a higher proportion of patients
achieved improvements in CGI-S (score ≥1) and PANSS
change (≥30%) than non-remitters. In an analysis of predictors
of remission using univariate and multivariate logistic regres-
sionmodels, CGI-S, PSP, and PANSS negative factor scores at
week 17, change in PANSS uncontrolled hostility/excitement
factor score, and change in PANSS anxiety/depression factor
score were identiﬁed as signiﬁcant variables inﬂuencing
remission.63
Due to the slow drug release proﬁle of the formulation,
PP3M is not intended in patients experiencing acute
exacerbation of schizophrenia and those who are currently
on oral risperidone or paliperidone ER, or those not cur-
rently receiving PP1M.31 Maintenance treatment with
PP3M should be initiated after the patient has adequately
responded and tolerated a ﬂexible dose range of PP1M for
at least 4 months. The last two doses of PP1M prior to
switching to PP3M is recommended to be the same, and
the patient should be clinically stable (based on clinical
judgment) and adequately tolerating PP1M before transi-
tioning to PP3M.31 The evaluation of adequate response
should reﬂect a high degree of symptomatic remission and
clinical stability at steady state of PP1M to determine the
correct dose of PP3M during transitioning to maintain the
desired exposure with no or minimal dose adjustment in
the future. Clinicians should be careful not to initiate
PP3M as a last resort in patients not responding to current
antipsychotic therapy.32
Safety and tolerability
The safety and tolerability proﬁle of PP1M has been exten-
sively described. Treatment-emergent adverse events
(TEAEs) of clinical interest are weight gain (13–27%), EPS-
related TEAEs (6–25%), potentially prolactin-related TEAEs
(2–29%), and glucose-related TEAEs (0–4%).21,25,26,65–67
Suicidality, tachycardia, and QT prolongation were among
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the other TEAEs reported with PP1M use with sporadic
incidences. The high NNH (16 to ∞) reported for selected
risk outcomes support the favorable safety proﬁle of PP1M.37
Overall, 62% of patients in the placebo-controlled
study (placebo group: 58%) and 68% of patients in the
non-inferiority study (PP1M group: 66%) experienced
TEAEs with PP3M treatment.33,34 The nature and fre-
quency of TEAEs were generally comparable between
PP1M and PP3M groups, and corroborate earlier reports
of PP1M.33,34 The NNH reported for overall EPS, akathi-
sia, headache, weight gain, nasopharyngitis, and use of
anticholinergic medications during the DB phase of the
study was high relative to placebo (160 to −132.6), sug-
gesting a low incidence of these TEAEs with PP3M. The
highest risks were reported for weight gain (NNH=18.9,
95% CI=9.1, 362.6) and akathisia (NNH=27.1, 95%
CI=12.3, −667.1) and lowest for dyskinesia (NNH=
−132.6, 95% CI=44.5, −23.2), with the negative NNH
values indicating that PP3M-treated patients had reduced
risk of dyskinesia events vs placebo.39 The likelihood of
being helped or harmed (LHH=NNH/NNT) ranged from
5.6–47.2 for relapse prevention vs each selected safety
outcome of PP3M relative to placebo, suggesting overall
therapeutic gain.39 Overall, NNHs for adverse events asso-
ciated with PP3M were comparable to PP1M (Table 5).37
The incidences of EPS-related TEAEs and time-to-
onset (TTO) and time-to-resolution (TTR) of these events
were similar between PP3M and PP1M.68 The reported
median TTO was 115 days (PP3M) and 98.5 days (PP1M),
and the median TTR was 36.5 days (PP1M) in OL, 91
days (PP3M) and 85.5 days (PP1M) in the DB phase of the
non-inferiority study.68 Despite the higher dose strength
and longer half-life of PP3M, no meaningful differences
were reported in the EPS-proﬁle of PP3M vs PP1M.
Reduced dosing frequency and low rate of EPS-related
TEAEs with PP3M implicate a positive impact on adher-
ence and overall QoL of patients and their caregivers.68
Similar results were observed for injection-site reaction
and pain, an important concern pertinent to LAIs from
a healthcare perspective.69 Low visual analog scale scores
suggested mild injection-site pain and reduction from DB
baseline to endpoint without notable differences between
PP3M (Mean [SD]=19.5 [20.7] to 15.6 [17.9]) and PP1M
(18.4 [20.4] to 15.5 [18.3]). Severity of injection-site
induration, redness, and swelling were mild, with low
frequency in both treatment groups, without any signiﬁ-
cant inﬂuence of the formulation difference.70 Overall, the
safety proﬁle of PP3M in the global patient population was
consistent with ﬁndings in the East Asian,71 European, and
Latin American sub-groups, suggesting an absence of
regional or ethnic inﬂuences.
Review of evidence
Increasing awareness of antipsychotic treatment efﬁcacy
for schizophrenia has led to broadening of treatment goals
to encompass speciﬁc clinical dimensions of the disease,
such as cognitive deﬁcits, negative symptoms, mood
symptoms, and, most importantly, relapses.72,73 Relapses
in schizophrenia are the leading causes of hospitalization
and worsening of social and occupational functioning, and
often lead to loss of progress when patients are participat-
ing in recovery-oriented programs.74 In this context, SGA-
LAI antipsychotics have been developed and examined
with regard to their potential beneﬁts.75 Evidence from
Table 5 Number needed to harm for selected adverse events with different formulations of paliperidone palmitate
PP3M PP1M
NNH (95% CI), adverse effects
Extrapyramidal symptoms
Akathisia 27.1 (12.3; −667.1) 205 (36.9; −70.8)
Tremor 80.0 (22.5; 67.3) 68.6 (22.5; −92.4)
Dyskinesia −132.6 (44.5; −23.2) 207 (33.0; −53.5)
Parkinsonism 160.0 (28.9; −49.8) ∞
Anticholinergic use 43.8 (10.9; −21.1) 29.8 (11.3; −48.7)
Weight gain 18.9 (9.1; 362.6) 15.8 (9.3; 39.5)
Headache 21.7 (9.6; −87.4) 217.9 (23.4; −30.2)
Nasopharyngitis 23.6 (11.0; −689.5) 105.6 (20.4; −34.4)
Abbreviations: CI, conﬁdence interval; NNH, number needed to harm; PP1M, paliperidone palmitate once-monthly; PP3M,paliperidone palmitate 3-monthly.
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RCTs of available LAIs have shown mixed results for the
advantages of LAIs over OAPs for relapse prevention in
schizophrenia.76–82 However, mirror image and cohort
studies have supported the superiority of LAIs over
OAPs for prevention of rehospitalizations,83,84 generally
without risk of greater or additional adverse effects in
RCTs79,85 and, even with some indication of lower mor-
tality than with OAPs.86
By virtue of longer plasma half-lives and continuous
antipsychotic exposure, LAI formulations are likely to
provide protracted relapse-free periods, even after treat-
ment interruption or discontinuation.87,88 In three simi-
larly-designed relapse prevention studies with different
formulations of paliperidone, patients in the placebo
group were ﬁrst stabilized on the corresponding paliper-
idone formulation (oral, PP1M, PP3M) before being
withdrawn.23 Discontinuation in these studies reﬂects
a situation that is common in real-world treatment settings,
where patients may interrupt or completely discontinue
their medication without notifying their physician. Thus,
ﬁndings of longer post-discontinuation time-to-relapse
bring improved clarity about clinical beneﬁts and efﬁcacy
for long-term treatment of schizophrenia with LAI formu-
lations having extended half-lives. However, clinicians
may have concerns that the longer half-life of PP3M
may not allow intermittent dose titrations or therapeutic
changes during the 3-month window to manage any poten-
tial adverse events.89 It is, therefore, critical to adequately
stabilize patients on PP1M before initiating PP3M to mini-
mize the chances of unknown or uncontrolled adverse
events. Also, a paradoxical decrease in adherence due to
the longer gap between physician visits that could delay
detection of worsening symptoms or signs of adverse
events has been postulated as a possible disadvantage of
longer-acting formulations such as PP3M.90
Beneﬁt–risk assessments drive clinical decision-
making, and quantitative analyses using effect size mea-
surements are reliable methods for evidence-based
research that offer a more objective approach.62
Measures of effect size, such as NNT, help establish
therapeutic beneﬁt. NNH refers to the magnitude of
adverse effects, and SMD suggest the magnitude of
effect for continuous efﬁcacy outcomes, adjusted for
differences in scale of measurement and measuring
inaccuracies.35,36,40 For interpretation of efﬁcacy data,
the SMD values are deﬁned as small (0.2), medium
(0.5), and large (0.8) effect sizes.91 In the absence of
sufﬁcient head-to-head comparisons between available
LAI antipsychotics, effect sizes are interpretable mea-
sures that allow comparison of observed clinical effects
and risks across distinct studies.92 Overall, low NNT for
relapse prevention and achieving minimally important
change (≥20%) in PANSS total scores suggest meaning-
ful efﬁcacy with a lower relapse risk and comparable
beneﬁts of PP3M and PP1M treatment. The SMDs for
all efﬁcacy outcomes also supported the comparative
efﬁcacy of the two PP LAIs, suggesting that the prob-
ability of patients improving was comparable between
PP3M and PP1M treatment.
Diagnostic classiﬁcation of schizophrenia into dis-
crete subtypes based on predominance of positive or
negative symptoms serves as a useful predictor of prog-
nosis and treatment response.93 This strategy supports
efforts to establish clinical and pathophysiological corre-
lations that help in patient selection for improved out-
comes, longitudinal approaches for better care, and
judgment of symptom relief.93,94 Prominence of positive
symptoms reﬂects a relatively routine course of disease
with better premorbid adjustment, superior treatment out-
comes with antipsychotic treatment, and a neurochemical
pathophysiology with minimal atrophy; in contrast, nega-
tive symptoms represent a more malignant disease course
with poor pre-morbid adjustment, compromised function-
ing and characteristic structural brain changes.94
Negative symptoms tend to linger during periods of clin-
ical stability, and can interfere with normal functioning.95
There is consistent evidence that available antipsychotics
predominantly treat positive symptoms with modest
effects on other domains of schizophrenia.96 A limited
number of antipsychotics are available for speciﬁc treat-
ment of negative symptoms of schizophrenia and in most
cases improvements are perceived as a consequence of
their effects on positive symptoms.95,97 Among available
evidence for antipsychotic monotherapy, clozapine and
aripiprazole did not show satisfactory efﬁcacy for
improving negative symptoms, whereas olanzapine
showed signiﬁcant (P≤0.05) improvements in PANSS
negative subscale vs haloperidol.98–100 In acutely ill
patients with schizophrenia and predominantly negative
symptoms, paliperidone ER signiﬁcantly improved nega-
tive symptoms when compared with placebo.101
Clinically relevant improvements in negative, depressive,
and anxiety symptoms and disorganized thoughts have
also been observed in patients with schizophrenia treated
with PP1M in a real-world setting.102 Sustained improve-
ments in positive and negative subscale and symptoms
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factor scores indicate the efﬁcacy of PP3M across the
spectrum of schizophrenia comprising major domains.
PP3M treatment could potentially be useful in treating
negative symptoms in schizophrenia, a symptom domain
with few therapeutic options.55
Remission is an important component of recovery in
patients with schizophrenia, and consolidated outcome
measures of remission can aid interpretation of sympto-
matic outcomes in clinical studies.41,44 The observed
remission rates for both PP3M and PP1M were high;
however, it should be noted that both PP3M studies were
of longer duration and implemented an enrichment design,
allowing clinically stable patients to enter the DB treat-
ment phase.33,34,103 Overall, the achievement of sympto-
matic remission on severity and duration indicate that the
reductions in symptoms are robust and sustained, under-
scoring the clinical utility of PP3M.
Functional disability in schizophrenia is a major obstacle
in everyday activities. Among several other factors, neuro-
cognitive deﬁcits (attention, memory, processing speed,
executive functioning, vigilance, and reasoning) and severity
of negative symptoms contribute to impaired functionality in
schizophrenia.104 Difﬁculty in succeeding at school or main-
taining a job, managing social relationships, living indepen-
dently, and the struggle to handle basic daily needs are
common challenges reported in patients with
schizophrenia.105 Functional remission is deﬁned as
a separate domain from clinical remission and is assessed
using performance-based scales to measure adequate levels
of psychosocial functioning.106,107 Therefore, functional
recovery (in addition to symptom control, delaying progres-
sion and relapse) is regarded an essential goal in the manage-
ment of schizophrenia, and broadly emphasizes the capacity
of a person to resume normal levels of social and occupa-
tional function, independent life, and remission in overt
behavioral symptoms.3,107 Collectively, parallel improve-
ments in symptomatic and functional domains by PP3M
can be an important consideration for use in the comprehen-
sive management of schizophrenia, including enabling
enhanced efﬁcacy of adjunctive psychosocial interventions.
Schizophrenia is still all too frequently an incapacitating
psychiatric disorder that can lead to a “burden of care”:
a complex concept that exerts emotional, psychological,
physical, and economic impacts on the lives of caregivers
for patients with schizophrenia.108,109 Although there is
a lack of consensus regarding any speciﬁc cluster of psy-
chotic symptoms maximally impacting the caregiver’s bur-
den, severity of symptoms would in all likelihood escalate
the burden.108 The functional status of patients and relapses
are also thought to directly impact caregiver burden by
hampering the patient’s psychosocial competency and abil-
ity to live an independent life, and increasing the risk of
rehospitalization.109,110 Additionally, it is established that
the increasing number of hospitalizations and severity of
illness in these patients will heighten caregiver burden.111
Although substantial evidence comparing the effectiveness
of SGA-LAIs and their effects on functioning and symptom
alleviation are available, data on caregiver burden assess-
ments are limited. A Spanish epidemiological study demon-
strated signiﬁcant beneﬁts (P=0.0018) on caregiver burden
among caregivers of patients using risperidone-LAI com-
pared with those on oral atypical antipsychotics based on
the Zarit caregiver burden scale.112 Overall, PP3M and
PP1M treatment correlated with positive reduction in the
caregiver burden, as well as an improved ability to cope
with the burden, potentially by addressing the refractory
nature and non-adherence associated with schizophrenia.
Formulation beneﬁts of LAIs may be the major reasons
for reductions in urging and worrying domains among
caregivers of patients on PP1M/PP3M treatment. Taken
together, caregivers beneﬁt from the patient’s use of LAI
therapy, as it dispels the need to negotiate daily for medica-
tion adherence, reducing caregiver’s struggle, and even-
tually de-stressing the patient–caregiver relationship. With
a longer half-life, negotiations during PP3M treatment are
needed just 4-times a year. From a patient’s perspective,
a formulation like PP3M is advantageous, as they need to
visit clinics less frequently for injections, especially beneﬁt-
ing patients who are away from home or traveling, etc. As
studies have shown a lack of any signiﬁcant adherence
advantage with monthly injected LAIs, it is important to
investigate correlations between observed patient preference
and positive attitudes on measurement of actual medication
adherence in patients using PP3M.113
The safety proﬁle of SGA-LAIs, such as olanzapine,
aripiprazole, risperidone, and PP, are generally analogous
to OAPs,79 except for the post-injection delirium/sedation
syndrome with olanzapine LAI.114 Other side-effects
include variable incidences of psychotic symptoms, EPS
events, and metabolic/endocrine-related TEAEs (weight
gain, hyperprolactinemia, and impaired glucose
metabolism).115 The higher NNH for EPS and weight
gain relative to placebo reﬂect lower incidences of these
TEAEs with PP3M.37 The safety proﬁle of PP3M, espe-
cially with regard to EPS-related events and weight gain,
could potentially mediate improvements in QoL.116
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Although this paper endeavors to reconcile research
ﬁndings for PP3M and bridge the gap between trial-based
outcomes and clinical applicability, the results described
here represent a well-characterized clinical study population
with schizophrenia, without distinct identiﬁcation of symp-
tom predominance or risk factors. Some limitations are
noted in the primary outcome reports, such as exclusion
of patients with a history of recent substance dependence
and patients with treatment-resistant illness, particularly
those that require clozapine. Since patients need to ﬁrst
tolerate and respond to PPIM before they switch to PP3M,
patients are enriched for tolerability to PP, and this may lead
to higher NNH levels for EPS and similar adverse
events.33,34 Also, the efﬁcacy and safety of PP3M were
determined in patients who were already responsive to
PP1M, thus limiting the generalizability of these ﬁndings
to a treatment-naïve population.117 However, it should be
noted that PP3M administration is prescribed only in
patients who have been clinically stabilized on PP1M, and
that clinically, long-term treatment is not provided to unse-
lected populations, but rather to enriched populations who
responded to and tolerated the medication acutely.
Interpretations of measurement-based outcomes should be
placed within a context to individual patient requirements
with a careful assessment of disease course, risk factors,
patient/caregiver outlook, and individual adverse event
proﬁle.3 Thus, large real-world trials of PP3M in an unse-
lected patient population, assessing more pragmatic out-
comes, are needed to eliminate the risk of selection bias,
improve external validity of ﬁndings, and provide more
exhaustive safety data for PP3M.90,118 Additionally,
approaches to identify and address common patient and
clinician-related barriers to LAI use in general, such as
social stigma, increased direct costs, limited clinical experi-
ence, and lack of control over medication, would ultimately
help improve treatment outcomes.119
Conclusion
Available evidence supports a prominent position for
PP3M in the current therapeutic armamentarium for schi-
zophrenia. High remission rates substantiate the differ-
ences in scores reported in clinical studies of PP3M, and
help to elucidate the magnitude of symptomatic improve-
ment and level of patient functioning, supporting the use
of PP3M in the maintenance treatment of schizophrenia.
Robust effect sizes for treatment effects and harm could
help clinicians in patient management and advising
patients about potential outcomes with PP3M.
Improvements in clinically important domains of schizo-
phrenia, such as negative symptoms and caregiver burden,
can be expected to beneﬁt patients, clinicians, and care-
givers alike. Future studies to further delineate potential
beneﬁcial outcomes with PP3M treatment in terms of
long-term effects, cost-effectiveness, and real-world
experiences would substantiate these ﬁndings.
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